美罗培南在持续静静脉血液滤过期间的单剂量药代动力学
Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration.
作者信息
Thalhammer F, Schenk P, Burgmann H, El Menyawi I, Hollenstein U M, Rosenkranz A R, Sunder-Plassmann G, Breyer S, Ratheiser K
机构信息
Department of Internal Medicine I, Division of Infectious Diseases, University of Vienna, A-1090 Vienna, Austria.
出版信息
Antimicrob Agents Chemother. 1998 Sep;42(9):2417-20. doi: 10.1128/AAC.42.9.2417.
Abstract
The pharmacokinetic properties of meropenem were investigated in nine critically ill patients treated by continuous venovenous hemofiltration (CVVH). All patients received one dose of 1 g of meropenem intravenously. High-flux polysulfone membranes were used as dialyzers. Meropenem levels were measured in plasma and ultrafiltrate by high-performance liquid chromatography. The total body clearance and elimination half-life were 143.7 +/- 18.6 ml/min and 2.46 +/- 0.41 h, respectively. The post- to prehemofiltration ratio of meropenem was 0.24 +/- 0.06. Peak plasma drug concentrations measured 60 min postinfusion were 28.1 +/- 2.7 microgram/ml, and trough levels after 6 h of CVVH were 6.6 +/- 1.5 microgram/ml. The calculated total daily meropenem requirement in these patients with acute renal failure and undergoing CVVH was 2,482 +/- 321 mg. Based on these data, we conclude that patients with severe infections who are undergoing CVVH can be treated effectively with 1 g of meropenem every 8 h.
摘要
在9例接受持续静静脉血液滤过（CVVH）治疗的重症患者中研究了美罗培南的药代动力学特性。所有患者均静脉注射1 g美罗培南。使用高通量聚砜膜作为透析器。通过高效液相色谱法测定血浆和超滤液中的美罗培南水平。总体清除率和消除半衰期分别为143.7±18.6 ml/min和2.46±0.41 h。美罗培南血液滤过后与滤过前的比率为0.24±0.06。输注后60分钟测得的血浆药物峰值浓度为28.1±2.7微克/毫升，CVVH 6小时后的谷浓度为6.6±1.5微克/毫升。这些急性肾衰竭且接受CVVH治疗的患者美罗培南的每日总需求量计算为2482±321 mg。基于这些数据，我们得出结论，正在接受CVVH治疗的重症感染患者每8小时使用1 g美罗培南可得到有效治疗。
相似文献
1
Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration.美罗培南在持续静静脉血液滤过期间的单剂量药代动力学
Antimicrob Agents Chemother. 1998 Sep;42(9):2417-20. doi: 10.1128/AAC.42.9.2417.
2
Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration.美罗培南在接受持续静静脉血液滤过的急性肾衰竭重症患者中的药代动力学
Clin Pharmacol Ther. 1999 Jan;65(1):50-7. doi: 10.1016/S0009-9236(99)70121-9.
3
Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration.接受持续静静脉血液滤过的重症患者美罗培南的药代动力学及给药方案
Crit Care Med. 2000 Oct;28(10):3412-6. doi: 10.1097/00003246-200010000-00006.
4
Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.连续静脉-静脉血液滤过治疗的危重症患者美罗培南的药代动力学：连续输注与间断推注给药的随机对照试验。
Int J Antimicrob Agents. 2015 Jan;45(1):41-5. doi: 10.1016/j.ijantimicag.2014.09.009. Epub 2014 Oct 18.
5
Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration.美罗培南在接受持续静脉-静脉血液滤过或血液透析滤过的重症监护病房患者中的药代动力学。
Crit Care Med. 2000 Mar;28(3):632-7. doi: 10.1097/00003246-200003000-00005.
6
[Pharmacokinetics of meropenem administered with prolonged infusion time in patients receiving continuous veno-venous hemofiltration].[接受持续静脉-静脉血液滤过的患者中延长输注时间给药的美罗培南的药代动力学]
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2012 Mar;24(3):145-8.
7
Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure.急性肾衰竭患者在持续静静脉血液滤过和血液透析滤过过程中美罗培南的清除情况。
J Antimicrob Chemother. 2000 May;45(5):701-4. doi: 10.1093/jac/45.5.701.
8
Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.脓毒症接受高容量连续性静脉-静脉血液滤过的危重症患者中的美罗培南剂量。
Antimicrob Agents Chemother. 2010 Jul;54(7):2974-8. doi: 10.1128/AAC.01582-09. Epub 2010 May 17.
9
Single-dose pharmacokinetics of ofloxacin during continuous venovenous hemofiltration in critical care patients.
Am J Kidney Dis. 2003 Aug;42(2):310-4. doi: 10.1016/s0272-6386(03)00656-5.
10
Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration.接受持续静脉-静脉血液滤过的重症患者美罗培南血浆水平与药效学要求的相关性
Chemotherapy. 2003 Dec;49(6):280-6. doi: 10.1159/000074527.
引用本文的文献
1
Phage-antibiotic combinations against : impact of methodological approaches on effect evaluation.噬菌体-抗生素联合疗法：方法学途径对疗效评估的影响
Front Microbiol. 2025 Mar 12;16:1530819. doi: 10.3389/fmicb.2025.1530819. eCollection 2025.
2
Analytical and Clinical Validation of Assays for Volumetric Absorptive Microsampling (VAMS) of Drugs in Different Blood Matrices: A Literature Review.分析和临床验证不同血液基质中药物容量吸收微采样（VAMS）分析物检测方法：文献综述。
Molecules. 2023 Aug 14;28(16):6046. doi: 10.3390/molecules28166046.
3
Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.群体药代动力学Meta 分析与连续肾脏替代治疗危重症患者美罗培南的剂量推荐
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0082222. doi: 10.1128/aac.00822-22. Epub 2022 Aug 25.
4
Ω76: A designed antimicrobial peptide to combat carbapenem- and tigecycline-resistant .Ω76：一种设计用于对抗碳青霉烯类和替加环素耐药的抗菌肽。
Sci Adv. 2019 Jul 24;5(7):eaax1946. doi: 10.1126/sciadv.aax1946. eCollection 2019 Jul.
5
Beta-lactam carryover in arterial and central venous catheters is negligible.动脉和中心静脉导管中的β-内酰胺残留量可忽略不计。
Clin Chim Acta. 2018 Nov;486:265-268. doi: 10.1016/j.cca.2018.08.008. Epub 2018 Aug 15.
6
A Robust Statistical Approach to Analyse Population Pharmacokinetic Data in Critically Ill Patients Receiving Renal Replacement Therapy.一种稳健的统计方法分析接受肾脏替代治疗的危重症患者的群体药动学数据。
Clin Pharmacokinet. 2019 Feb;58(2):263-270. doi: 10.1007/s40262-018-0690-1.
7
Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam.描述肾脏替代治疗模式和参数对美罗培南和沃班巴坦药代动力学的影响。
Antimicrob Agents Chemother. 2018 Sep 24;62(10). doi: 10.1128/AAC.01306-18. Print 2018 Oct.
8
Pharmacokinetics of Continuous Infusion Meropenem With Concurrent Extracorporeal Life Support and Continuous Renal Replacement Therapy: A Case Report.持续输注美罗培南并同时进行体外生命支持和连续性肾脏替代治疗的药代动力学：一例报告
J Pediatr Pharmacol Ther. 2016 Jan-Feb;21(1):92-7. doi: 10.5863/1551-6776-21.1.92.
9
Doripenem Treatment during Continuous Renal Replacement Therapy.持续肾脏替代治疗期间的多利培南治疗
Antimicrob Agents Chemother. 2015 Dec 28;60(3):1687-94. doi: 10.1128/AAC.01801-15.
10
Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements.美罗培南在脓毒性休克及接受持续肾脏替代治疗的重症患者中的群体药代动力学：残余尿量对剂量需求的影响
Antimicrob Agents Chemother. 2015 Sep;59(9):5520-8. doi: 10.1128/AAC.00712-15. Epub 2015 Jun 29.
本文引用的文献
1
Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration.亚胺培南-西司他丁在接受持续静静脉血液滤过的危重症患者中的药代动力学
Antimicrob Agents Chemother. 1997 Dec;41(12):2640-5. doi: 10.1128/AAC.41.12.2640.
2
Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH).哌拉西林和他唑巴坦在接受持续静脉-静脉血液滤过（CVVH）治疗的肾衰竭重症患者中的药代动力学。
Intensive Care Med. 1997 Aug;23(8):873-7. doi: 10.1007/s001340050424.
3
Single-dose pharmacokinetics of teicoplanin during hemodialysis therapy using high-flux polysulfone membranes.使用高通量聚砜膜进行血液透析治疗期间替考拉宁的单剂量药代动力学。
Wien Klin Wochenschr. 1997 May 23;109(10):362-5.
4
Antimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic model.碳青霉烯类抗生素持续给药与间歇给药在体外动态模型中的抗菌效果
Antimicrob Agents Chemother. 1997 Jun;41(6):1215-9. doi: 10.1128/AAC.41.6.1215.
5
Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers.美罗培南与其他广谱抗菌药物对在26个北美中心测试的随机选择和挑选出的耐药临床分离株的体外活性比较。
Clin Infect Dis. 1997 Feb;24 Suppl 2:S238-48. doi: 10.1093/clinids/24.supplement_2.s238.
6
Multiple-dose pharmacokinetics of cefpirome in long-term hemodialysis with high-flux membranes.头孢匹罗在高通量膜长期血液透析中的多剂量药代动力学
Clin Pharmacol Ther. 1996 Dec;60(6):645-50. doi: 10.1016/S0009-9236(96)90212-X.
7
Basic mechanisms and definitions for continuous renal replacement therapies.
Int J Artif Organs. 1996 Feb;19(2):95-9.
8
Antimicrobial prescribing in patients on haemofiltration.
J Antimicrob Chemother. 1995 Nov;36(5):773-80. doi: 10.1093/jac/36.5.773.
9
Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease.美罗培南在不同程度肾功能患者（包括终末期肾病患者）中的药代动力学。
Antimicrob Agents Chemother. 1993 Feb;37(2):229-33. doi: 10.1128/AAC.37.2.229.
10
Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration.连续性血液滤过治疗的急性或慢性肾衰竭患者亚胺培南药代动力学比较
Am J Kidney Dis. 1993 Feb;21(2):172-9. doi: 10.1016/s0272-6386(12)81089-4.
Zotero 插件